Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sontuzumab (AS1402), a humanized IgG1κ monoclonal antibody targeting MUC1, exhibits high affinity, with a dissociation constant (Kd) of approximately 1 nM for the extracellular peptide sequence PDTR of MUC1. It is utilized in breast cancer research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Sontuzumab (AS1402), a humanized IgG1κ monoclonal antibody targeting MUC1, exhibits high affinity, with a dissociation constant (Kd) of approximately 1 nM for the extracellular peptide sequence PDTR of MUC1. It is utilized in breast cancer research [1]. |
In vitro | Sontuzumab (huHMFG-1; 0-25 μg/mL) induces antibody-dependent cellular cytotoxicity (ADCC) in the following cell lines: breast cancer ZR-75-1 cells, three myeloid tumor cell lines from breast cancer patients (KM22, 1590, HG15), and Chinese hamster ovary (CHO) cells transfected with the human MUC1 gene. Cell lines that do not express human MUC1 are insensitive to ADCC when Sontuzumab is present [1] [2]. |
Synonyms | huHMFG-1, AS1402 |
Molecular Weight | N/A |
CAS No. | 372075-37-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sontuzumab 372075-37-1 AS-1402 AS 1402 huHMFG-1 AS1402 inhibitor inhibit